Bionik Laboratories (BNKL) Stock Statistics & Valuation Metrics

Bionik Laboratories has a market cap or net worth of $1.25K. The enterprise value is ―.

Bionik Laboratories has 12,480,263 shares outstanding. The number of shares has decreased by -2.65% in one year.

Bionik Laboratories’s return on equity (ROE) is 3.01 and return on invested capital (ROIC) is -448.84%.

The current PE Ratio of Bionik Laboratories is ―. Bionik Laboratories’s PEG ratio is 0.00764.

In the last 12 months, Bionik Laboratories had revenue of 1.81M and earned -4.95M in profits. Earnings per share was -0.72.

In the last 12 months, operating cash flow was -3.39M and capital expenditures 99.57K, giving a free cash flow of -3.29M billion.

Bionik Laboratories pays an annual dividend of ―, resulting in a dividend yield of ―

Bionik Laboratories upcoming earnings date is ―, ―.

Bionik Laboratories as a current ratio of 1.20, with Debt / Equity ratio of -147.04%

In the past 12 months, Bionik Laboratories has paid 0.00 in taxes.

Bionik Laboratories EV to EBITDA ratio is -0.99, with an EV/FCF ratio of -1.40.

Bionik Laboratories has $427.38K in cash and marketable securities with $2.41M in debt, giving a net cash position of -$1.98M billion.

Gross margin is 54.83%, with operating margin of -267.29%, and net profit margin of -273.99%.

The average price target for Bionik Laboratories is ―, which is 11.43% higher than the current price. The consensus rating is ―